Insider Selling: Teleflex Incorporated (TFX) Director Sells 200 Shares of Stock
Teleflex Incorporated (NYSE:TFX) Director Stephen K. M.D. Klasko sold 200 shares of the stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $237.18, for a total value of $47,436.00. Following the sale, the director now directly owns 8,080 shares in the company, valued at approximately $1,916,414.40. The sale was disclosed in a filing with the SEC, which is accessible through this link.
Teleflex Incorporated (NYSE TFX) traded up $14.70 during trading hours on Friday, hitting $256.41. The company’s stock had a trading volume of 439,291 shares, compared to its average volume of 227,863. The company has a current ratio of 4.72, a quick ratio of 2.76 and a debt-to-equity ratio of 0.88. The stock has a market cap of $11,478.55, a PE ratio of 31.50, a PEG ratio of 2.45 and a beta of 1.05.
Teleflex (NYSE:TFX) last released its quarterly earnings results on Thursday, November 2nd. The medical technology company reported $2.12 earnings per share for the quarter, beating the consensus estimate of $2.01 by $0.11. Teleflex had a return on equity of 16.27% and a net margin of 12.41%. The firm had revenue of $534.70 million for the quarter, compared to analysts’ expectations of $522.94 million. During the same quarter last year, the firm posted $1.80 EPS. The company’s revenue was up 17.3% compared to the same quarter last year. equities analysts forecast that Teleflex Incorporated will post 8.32 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, December 15th. Shareholders of record on Wednesday, November 15th will be issued a $0.34 dividend. The ex-dividend date of this dividend is Tuesday, November 14th. This represents a $1.36 annualized dividend and a dividend yield of 0.53%. Teleflex’s payout ratio is currently 24.82%.
COPYRIGHT VIOLATION WARNING: “Insider Selling: Teleflex Incorporated (TFX) Director Sells 200 Shares of Stock” was reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another site, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/11/03/insider-selling-teleflex-incorporated-tfx-director-sells-200-shares-of-stock.html.
Several large investors have recently added to or reduced their stakes in the business. BNP Paribas Arbitrage SA raised its holdings in shares of Teleflex by 133.0% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 47,109 shares of the medical technology company’s stock valued at $11,399,000 after acquiring an additional 26,894 shares in the last quarter. Swiss National Bank raised its holdings in shares of Teleflex by 1.2% in the 3rd quarter. Swiss National Bank now owns 165,600 shares of the medical technology company’s stock valued at $40,070,000 after acquiring an additional 2,000 shares in the last quarter. Scout Investments Inc. purchased a new stake in shares of Teleflex in the 3rd quarter valued at about $14,156,000. Principal Financial Group Inc. raised its holdings in shares of Teleflex by 0.8% in the 3rd quarter. Principal Financial Group Inc. now owns 615,382 shares of the medical technology company’s stock valued at $148,905,000 after acquiring an additional 4,984 shares in the last quarter. Finally, Oregon Public Employees Retirement Fund raised its holdings in shares of Teleflex by 74.2% in the 3rd quarter. Oregon Public Employees Retirement Fund now owns 28,216 shares of the medical technology company’s stock valued at $6,827,000 after acquiring an additional 12,017 shares in the last quarter. 89.78% of the stock is currently owned by hedge funds and other institutional investors.
A number of analysts recently issued reports on TFX shares. BidaskClub cut Teleflex from a “buy” rating to a “hold” rating in a report on Monday, July 31st. Jefferies Group LLC reissued a “buy” rating and set a $230.00 price objective on shares of Teleflex in a report on Thursday, August 3rd. Needham & Company LLC reissued a “buy” rating on shares of Teleflex in a report on Friday, August 4th. Deutsche Bank AG reissued a “buy” rating and set a $238.00 price objective (up previously from $220.00) on shares of Teleflex in a report on Wednesday, August 9th. Finally, Zacks Investment Research cut Teleflex from a “buy” rating to a “hold” rating in a report on Thursday, August 24th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $271.88.
Teleflex Company Profile
Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).
Receive News & Ratings for Teleflex Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.